vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and READING INTERNATIONAL INC (RDI). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $50.3M, roughly 1.5× READING INTERNATIONAL INC). READING INTERNATIONAL INC runs the higher net margin — -5.1% vs -9.6%, a 4.5% gap on every dollar of revenue. On growth, READING INTERNATIONAL INC posted the faster year-over-year revenue change (-14.2% vs -16.8%). Over the past eight quarters, READING INTERNATIONAL INC's revenue compounded faster (5.6% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

The Reading Company was a Philadelphia-headquartered railroad that provided passenger and freight transport in eastern Pennsylvania and neighboring states from 1924 until its acquisition by Conrail in 1976.

BIOX vs RDI — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.5× larger
BIOX
$77.6M
$50.3M
RDI
Growing faster (revenue YoY)
RDI
RDI
+2.6% gap
RDI
-14.2%
-16.8%
BIOX
Higher net margin
RDI
RDI
4.5% more per $
RDI
-5.1%
-9.6%
BIOX
Faster 2-yr revenue CAGR
RDI
RDI
Annualised
RDI
5.6%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
RDI
RDI
Revenue
$77.6M
$50.3M
Net Profit
$-7.4M
$-2.6M
Gross Margin
46.8%
Operating Margin
9.3%
-1.9%
Net Margin
-9.6%
-5.1%
Revenue YoY
-16.8%
-14.2%
Net Profit YoY
-20.2%
-14.5%
EPS (diluted)
$-0.12
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
RDI
RDI
Q4 25
$50.3M
Q3 25
$77.6M
$52.2M
Q2 25
$60.4M
Q1 25
$60.6M
$40.2M
Q4 24
$98.8M
$58.6M
Q3 24
$93.3M
$60.1M
Q2 24
$46.8M
Q1 24
$84.0M
$45.1M
Net Profit
BIOX
BIOX
RDI
RDI
Q4 25
$-2.6M
Q3 25
$-7.4M
$-4.2M
Q2 25
$-2.7M
Q1 25
$-1.6M
$-4.8M
Q4 24
$605.2K
$-2.2M
Q3 24
$-6.2M
$-7.0M
Q2 24
$-12.8M
Q1 24
$9.8M
$-13.2M
Gross Margin
BIOX
BIOX
RDI
RDI
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
BIOX
BIOX
RDI
RDI
Q4 25
-1.9%
Q3 25
9.3%
-0.6%
Q2 25
4.8%
Q1 25
1.5%
-17.2%
Q4 24
14.5%
2.6%
Q3 24
2.5%
-0.6%
Q2 24
-16.4%
Q1 24
15.7%
-16.7%
Net Margin
BIOX
BIOX
RDI
RDI
Q4 25
-5.1%
Q3 25
-9.6%
-8.0%
Q2 25
-4.4%
Q1 25
-2.6%
-11.8%
Q4 24
0.6%
-3.8%
Q3 24
-6.6%
-11.7%
Q2 24
-27.4%
Q1 24
11.6%
-29.4%
EPS (diluted)
BIOX
BIOX
RDI
RDI
Q4 25
$-0.11
Q3 25
$-0.12
$-0.18
Q2 25
$-0.12
Q1 25
$-0.02
$-0.21
Q4 24
$0.00
$-0.11
Q3 24
$-0.10
$-0.31
Q2 24
$-0.57
Q1 24
$0.14
$-0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
RDI
RDI
Cash + ST InvestmentsLiquidity on hand
$15.5M
$10.5M
Total DebtLower is stronger
$185.1M
Stockholders' EquityBook value
$288.3M
$-18.2M
Total Assets
$734.9M
$434.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
RDI
RDI
Q4 25
$10.5M
Q3 25
$15.5M
$8.1M
Q2 25
$9.1M
Q1 25
$38.5M
$5.9M
Q4 24
$29.2M
$12.4M
Q3 24
$32.3M
$10.1M
Q2 24
$9.3M
Q1 24
$16.4M
$7.5M
Total Debt
BIOX
BIOX
RDI
RDI
Q4 25
$185.1M
Q3 25
Q2 25
Q1 25
Q4 24
$202.7M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BIOX
BIOX
RDI
RDI
Q4 25
$-18.2M
Q3 25
$288.3M
$-12.1M
Q2 25
$-7.7M
Q1 25
$345.0M
$-8.1M
Q4 24
$346.3M
$-4.4M
Q3 24
$346.0M
$1.6M
Q2 24
$6.5M
Q1 24
$348.5M
$18.0M
Total Assets
BIOX
BIOX
RDI
RDI
Q4 25
$434.9M
Q3 25
$734.9M
$435.2M
Q2 25
$438.1M
Q1 25
$798.2M
$441.0M
Q4 24
$835.2M
$471.0M
Q3 24
$827.3M
$495.7M
Q2 24
$494.9M
Q1 24
$836.1M
$494.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
RDI
RDI
Operating Cash FlowLast quarter
$14.4M
$4.3M
Free Cash FlowOCF − Capex
$4.1M
FCF MarginFCF / Revenue
8.2%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-2.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
RDI
RDI
Q4 25
$4.3M
Q3 25
$14.4M
$295.0K
Q2 25
$1.6M
Q1 25
$23.3M
$-7.7M
Q4 24
$-5.4M
$8.0M
Q3 24
$5.2M
$1.3M
Q2 24
$-10.4M
Q1 24
$-17.4M
$-2.8M
Free Cash Flow
BIOX
BIOX
RDI
RDI
Q4 25
$4.1M
Q3 25
$-246.0K
Q2 25
$1.2M
Q1 25
$-8.0M
Q4 24
$7.0M
Q3 24
$-1.1M
Q2 24
$-10.6M
Q1 24
$-4.7M
FCF Margin
BIOX
BIOX
RDI
RDI
Q4 25
8.2%
Q3 25
-0.5%
Q2 25
1.9%
Q1 25
-19.8%
Q4 24
12.0%
Q3 24
-1.8%
Q2 24
-22.7%
Q1 24
-10.4%
Capex Intensity
BIOX
BIOX
RDI
RDI
Q4 25
0.3%
Q3 25
1.0%
Q2 25
0.6%
Q1 25
0.6%
Q4 24
1.7%
Q3 24
4.0%
Q2 24
0.5%
Q1 24
4.3%
Cash Conversion
BIOX
BIOX
RDI
RDI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-8.85×
Q3 24
Q2 24
Q1 24
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

RDI
RDI

Cinema Exhibition Segment$46.9M93%
Real Estate Revenue$3.4M7%

Related Comparisons